Clinical Sciences Core

项目总结 第三海岸CFAR核心C：临床科学核心(CSC) 2017年，芝加哥新增艾滋病毒感染人数有所下降，92%的确诊艾滋病毒感染者是 在确诊后12个月内与护理联系起来。然而，主要问题仍然存在。只有36%的人与 2017年艾滋病毒(PLWH)仍在护理中，只有48%实现了病毒抑制。此外，成功的 抗逆转录病毒疗法(ART)导致了老年PLWH人口的增加，这使得与衰老相关的 并存是对受到很好抑制的PLWH的直接威胁，最终是一个日益严重的公共卫生挑战。 因此，继续需要提高治疗和艾滋病毒预防的实际效果。这个 临床科学核心(CSC)将在以下基础上加强对解决这些问题的研究的支持 我们在西北大学(NU)内部和之间建立的基础设施和联系 芝加哥大学(UC)。不断扩大的社区组织合作伙伴群体也增加了覆盖范围 服务提供商，现在尤其包括Howard Brown Health(HBH)，该公司已将网站扩展到大多数地区 需要并长期致力于芝加哥LGBTQ社区的健康。提供CSC专业知识 和跨学科和机构的服务是我们使命的核心，并支持发展新的 科学伙伴关系。这些专业知识包括关于简化艺术和研究的人体对象研究 与衰老相关的合并症和炎症。我们成就卓著、充满活力的临床信息学小组 (CIG)将继续推动研究人员获得复杂的计算、分析技术 电子健康记录(EHR)衍生的数据，以及为研究参与者提供的新兴数字工具。中纪委还 强调传播研究成果和最佳做法，并与社区合作 诊所和艾滋病毒筛查计划。CSC的长期目标是大幅增加 杰出的临床研究人员，以及他们可以利用的跨学科资源，以便为 这些发现将推动我们结束艾滋病毒流行。中证委为实现这一目标而制定的具体目标 是：1)支持与艾滋病毒感染者和高危参与者互动的临床研究，和/或获得和 研究临床数据和样本；2)催化和支持关于非艾滋病的新研究 共病，包括艾滋病毒炎症和加速衰老的临床表型和病理生理学； 3)扩大研究参与者、临床艾滋病毒研究人员、艾滋病毒护理人员之间的研究合作和联系 供应商、其他实施伙伴和受训人员。在下一个项目期，CSC承诺扩大 作为抗逆转录病毒治疗的主要贡献者，关于PLWH中非艾滋病合并症的研究的范围和影响 TC CFAR的总体目标2.CSC的每个具体目标都有助于实现关于非艾滋病合并症的总体目标2， 其目的是增加CSC用户对艾滋病毒老化和共病的跨学科研究。

PROJECT SUMMARY THIRD COAST CFAR CORE C: CLINICAL SCIENCES CORE (CSC) In 2017, new HIV infections in Chicago decreased somewhat, and 92% of persons diagnosed with HIV were linked to care within 12 months of diagnosis. However, major problems remain. Only 36% of persons living with HIV (PLWH) in 2017 were retained in care, and only 48% achieved viral suppression. In addition, successes of antiretroviral therapy (ART) have led to a rising population of older PLWH, which has made aging-related comorbidities a proximate threat to well-suppressed PLWH and ultimately an increasing public health challenge. Thus, the needs to improve real-world effectiveness of treatments, as well as HIV prevention, continue. The Clinical Sciences Core (CSC) will intensify its support of research that addresses these problems, building on infrastructure and linkages that we have created within and between Northwestern University (NU) and the University of Chicago (UC). An expanding group of community organization partners also increases reach to service providers, now notably including Howard Brown Health (HBH) that has expanded sites to areas of most need and has a long commitment to the health of the LGBTQ community in Chicago. Offering CSC expertise and services across disciplines and institutions is central to our mission and supports the development of new scientific partnerships. This expertise includes human subjects research on streamlining ART and studying aging-associated comorbidities and inflammation. Our accomplished and dynamic Clinical Informatics Group (CIG) will continue advancing researcher access to sophisticated techniques for computation, analyses of Electronic Health Record (EHR)-derived data, and emerging digital tools for research participants. The CSC also emphasizes disseminating research findings and best practices, as well as engaging with community-based clinics and HIV screening programs. The long-term goal of the CSC is to significantly increase the number of outstanding clinical investigators, and the trans-disciplinary resources available to them, in order to fuel discoveries that will propel us towards the end of the HIV epidemic. The CSC’s specific aims to reach this goal are to: 1) support clinical research that interacts with HIV-infected and at-risk participants, and/or obtains and studies clinical data and specimens from them; 2) catalyze and support new research on non-AIDS comorbidities, including clinical phenotyping and pathophysiology of inflammation and accelerated aging in HIV; 3) expand research collaborations and linkages among study participants, clinical HIV researchers, HIV care providers, other implementation partners and trainees. In the next project period, the CSC commits to expanding the scope and impact of research on non-AIDS comorbidities among PLWH on ART as a major contributor to TC CFAR’s Overall aim 2. Each of the CSC specific aims contributes to Overall aim 2 on non-AIDS comorbidities, and the intent is to increase the CSC users’ trans-disciplinary research on aging and comorbidities in HIV.